(ASH) Ashland Global Holdings - Overview
Stock: Additives, Ingredients, Binders, Coatings, Emulsifiers
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.96% |
| Yield on Cost 5y | 2.62% |
| Yield CAGR 5y | 8.86% |
| Payout Consistency | 93.5% |
| Payout Ratio | 53.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 32.2% |
| Relative Tail Risk | -11.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.12 |
| Alpha | -13.92 |
| Character TTM | |
|---|---|
| Beta | 1.096 |
| Beta Downside | 1.189 |
| Drawdowns 3y | |
|---|---|
| Max DD | 53.78% |
| CAGR/Max DD | -0.24 |
Description: ASH Ashland Global Holdings January 14, 2026
Ashland Inc. (NYSE:ASH) manufactures additives and specialty ingredients for a global customer base across North and Latin America, Europe, and Asia-Pacific. The company operates four segments: Life Sciences (pharmaceutical and nutrition solutions, agricultural chemicals, diagnostics, fine chemicals), Personal Care (nature-derived, biodegradable ingredients for oral care and household products), Specialty Additives (rheology modifiers, surfactants, advanced ceramics for catalytic converters, capacitors, solar cells, and textile printing), and Intermediates (1,4-butanediol and related solvents such as N-methyl-2-pyrrolidone). Its product portfolio serves end-markets ranging from architectural coatings and construction to food & beverage, energy, and pharma.
In FY 2023 Ashland reported revenue of roughly $2.5 billion, with an adjusted EBITDA margin of ~12%, reflecting steady pricing power in high-margin specialty chemicals. The segment most sensitive to macro trends is Specialty Additives, where demand is being driven by the global shift toward low-carbon, recyclable materials and the growth of electric-vehicle catalytic converter production. Additionally, the Life Sciences segment benefits from a 6-year compound annual growth rate (CAGR) of ~5% in the global pharmaceutical excipients market, supported by rising generic drug pipelines and increased oral-solid-dose formulations.
For a deeper, data-rich assessment of Ashland’s valuation dynamics, you may find ValueRay’s analytical toolkit worth exploring.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -844.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -2.57 > 1.0 |
| NWC/Revenue: 38.58% < 20% (prev 33.35%; Δ 5.23% < -1%) |
| CFO/TA 0.04 > 3% & CFO 200.0m > Net Income -844.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.0m) vs 12m ago -6.12% < -2% |
| Gross Margin: 30.08% > 18% (prev 0.29%; Δ 2979 % > 0.5%) |
| Asset Turnover: 35.55% > 50% (prev 37.45%; Δ -1.89% > 0%) |
| Interest Coverage Ratio: -12.28 > 6 (EBITDA TTM -512.0m / Interest Expense TTM 61.0m) |
Altman Z'' 2.36
| A: 0.15 (Total Current Assets 1.12b - Total Current Liabilities 420.0m) / Total Assets 4.62b |
| B: 0.49 (Retained Earnings 2.29b / Total Assets 4.62b) |
| C: -0.15 (EBIT TTM -749.0m / Avg Total Assets 5.13b) |
| D: 0.69 (Book Value of Equity 1.89b / Total Liabilities 2.73b) |
| Altman-Z'' Score: 2.36 = BBB |
Beneish M -3.48
| DSRI: 0.96 (Receivables 201.0m/243.0m, Revenue 1.82b/2.11b) |
| GMI: 0.97 (GM 30.08% / 29.28%) |
| AQI: 0.88 (AQ_t 0.48 / AQ_t-1 0.54) |
| SGI: 0.86 (Revenue 1.82b / 2.11b) |
| TATA: -0.23 (NI -844.0m - CFO 200.0m) / TA 4.62b) |
| Beneish M-Score: -3.48 (Cap -4..+1) = AA |
What is the price of ASH shares?
Over the past week, the price has changed by +4.91%, over one month by +4.77%, over three months by +28.59% and over the past year by +1.48%.
Is ASH a buy, sell or hold?
- StrongBuy: 6
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ASH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 65.2 | 1.6% |
| Analysts Target Price | 65.2 | 1.6% |
| ValueRay Target Price | 68.8 | 7.3% |
ASH Fundamental Data Overview February 03, 2026
P/S = 1.5344
P/B = 1.4837
P/EG = -1.36
Revenue TTM = 1.82b USD
EBIT TTM = -749.0m USD
EBITDA TTM = -512.0m USD
Long Term Debt = 1.38b USD (from longTermDebt, last quarter)
Short Term Debt = 21.0m USD (from shortTermDebt, last quarter)
Debt = 1.49b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.28b USD (from netDebt column, last quarter)
Enterprise Value = 4.07b USD (2.80b + Debt 1.49b - CCE 215.0m)
Interest Coverage Ratio = -12.28 (Ebit TTM -749.0m / Interest Expense TTM 61.0m)
EV/FCF = 35.08x (Enterprise Value 4.07b / FCF TTM 116.0m)
FCF Yield = 2.85% (FCF TTM 116.0m / Enterprise Value 4.07b)
FCF Margin = 6.36% (FCF TTM 116.0m / Revenue TTM 1.82b)
Net Margin = -46.25% (Net Income TTM -844.0m / Revenue TTM 1.82b)
Gross Margin = 30.08% ((Revenue TTM 1.82b - Cost of Revenue TTM 1.28b) / Revenue TTM)
Gross Margin QoQ = 33.26% (prev 28.51%)
Tobins Q-Ratio = 0.88 (Enterprise Value 4.07b / Total Assets 4.62b)
Interest Expense / Debt = 1.08% (Interest Expense 16.0m / Debt 1.49b)
Taxrate = 48.44% (31.0m / 64.0m)
NOPAT = -386.2m (EBIT -749.0m * (1 - 48.44%)) [loss with tax shield]
Current Ratio = 2.68 (Total Current Assets 1.12b / Total Current Liabilities 420.0m)
Debt / Equity = 0.79 (Debt 1.49b / totalStockholderEquity, last quarter 1.89b)
Debt / EBITDA = -2.50 (negative EBITDA) (Net Debt 1.28b / EBITDA -512.0m)
Debt / FCF = 11.02 (Net Debt 1.28b / FCF TTM 116.0m)
Total Stockholder Equity = 2.23b (last 4 quarters mean from totalStockholderEquity)
RoA = -16.44% (Net Income -844.0m / Total Assets 4.62b)
RoE = -37.81% (Net Income TTM -844.0m / Total Stockholder Equity 2.23b)
RoCE = -20.71% (EBIT -749.0m / Capital Employed (Equity 2.23b + L.T.Debt 1.38b))
RoIC = -10.72% (negative operating profit) (NOPAT -386.2m / Invested Capital 3.60b)
WACC = 6.70% (E(2.80b)/V(4.28b) * Re(9.96%) + D(1.49b)/V(4.28b) * Rd(1.08%) * (1-Tc(0.48)))
Discount Rate = 9.96% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.03%
[DCF Debug] Terminal Value 76.55% ; FCFF base≈184.4m ; Y1≈121.0m ; Y5≈55.2m
Fair Price DCF = 2.94 (EV 1.41b - Net Debt 1.28b = Equity 134.7m / Shares 45.8m; r=6.70% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -53.35 | EPS CAGR: -50.52% | SUE: -1.48 | # QB: 0
Revenue Correlation: -68.01 | Revenue CAGR: -1.82% | SUE: -0.22 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.12 | Chg30d=-0.020 | Revisions Net=+1 | Analysts=7
EPS current Year (2026-09-30): EPS=3.95 | Chg30d=+0.010 | Revisions Net=-2 | Growth EPS=+17.0% | Growth Revenue=+2.2%
EPS next Year (2027-09-30): EPS=4.68 | Chg30d=-0.055 | Revisions Net=-4 | Growth EPS=+18.3% | Growth Revenue=+3.6%